Researchers have reported success with an optogenetic gene therapy approach designed to restore partial vision in people with advanced blindness. The technique, which employs methods honored with the 2026 Nobel prize in physiology or medicine, was initially demonstrated in a single patient in 2021 and has now been evaluated in a trial involving that original participant plus nine additional subjects.
All ten trial participants had advanced retinitis pigmentosa, a genetic disorder affecting light-sensitive cells in the retina. The therapy works by delivering genetic instructions through a harmless synthetic virus injected into the eye, enabling surviving ganglion cells to become light-sensitive. Patients subsequently wear specialized goggles that convert visual images into light pulses, activating the treated cells to produce monochrome vision. The approach does not depend on the specific genetic cause of vision loss.
Researchers treated only the eye with the worst vision in each participant and followed outcomes for up to five years. Six of the ten patients experienced clinically meaningful improvements in light sensitivity following treatment. Several participants demonstrated improvements in practical tasks while wearing the light-stimulating goggles, including detecting and locating objects and navigating spaces. Participants who engaged in more training with the goggles showed better task performance.
Safety results were favorable, with only one severe eye-related side effect occurring, which resolved within minutes. No systemic side effects related to the therapy were observed. However, researchers acknowledge current limitations, noting that treated patients can detect objects but cannot yet detect faces. This limitation stems from the ring-like arrangement of treated ganglion cells around the fovea, the retina’s central region responsible for sharp vision.
Research leaders indicated plans to work toward restoring higher-resolution vision, with goals potentially achievable within five to ten years. The study was published in the New England Journal of Medicine.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI